FDA Approves First Gene Therapies for Sickle Cell Disease
U.S. Food and Drug Administration
The FDA granted the approval of Casgevy to Vertex Pharmaceuticals Inc., and Lyfgenia to Bluebird Bio Inc.
Sign up for all of our 2024 digital events with one click
IVDR-compliant products help boost patient safety as well as future-proof customer supply chains